Two Sigma Advisers LP Buys 357,500 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Two Sigma Advisers LP lifted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 44.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,157,500 shares of the company's stock after acquiring an additional 357,500 shares during the quarter. Two Sigma Advisers LP owned about 0.51% of Gossamer Bio worth $1,047,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in GOSS. Octagon Capital Advisors LP lifted its position in shares of Gossamer Bio by 99.7% during the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock worth $16,599,000 after purchasing an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in Gossamer Bio by 52.7% in the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock valued at $7,968,000 after buying an additional 3,041,058 shares during the last quarter. Monaco Asset Management SAM grew its stake in shares of Gossamer Bio by 39.5% during the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after acquiring an additional 1,520,721 shares in the last quarter. Allostery Investments LP purchased a new stake in shares of Gossamer Bio during the fourth quarter worth about $555,000. Finally, Silverarc Capital Management LLC lifted its stake in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock worth $5,583,000 after acquiring an additional 526,495 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GOSS has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a report on Friday, May 16th. Finally, The Goldman Sachs Group increased their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th.

Gossamer Bio Trading Up 4.1%

Shares of NASDAQ:GOSS traded up $0.05 during midday trading on Monday, reaching $1.16. The company had a trading volume of 1,591,064 shares, compared to its average volume of 1,530,925. The company has a fifty day simple moving average of $1.00 and a two-hundred day simple moving average of $1.01. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market cap of $262.53 million, a price-to-earnings ratio of -3.61 and a beta of 1.82. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million. Research analysts predict that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.